Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis

American Journal of Managed Care

Volumn 19, Issue 2 SUPPL, 2013, Pages

  Tullman, Mark J ^a  

^a MISSOURI BAPTIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FREE RADICAL; GAMMA INTERFERON; GLUTAMIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DRB1 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; MYELIN ASSOCIATED GLYCOPROTEIN; NITRIC OXIDE; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ACINETOBACTER INFECTION; AFRICAN AMERICAN; ANTIGEN PRESENTING CELL; ARTICLE; ASTROCYTE; BALANCE IMPAIRMENT; BIRTH CONTROL; BLADDER DYSFUNCTION; BLURRED VISION; CAUCASIAN; CD4+ T LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; CHILDBIRTH; CHLAMYDIAL PNEUMONIA; CLINICAL CLASSIFICATION; DEMYELINATION; DENDRITIC CELL; DIPLOPIA; DIZYGOTIC TWINS; EPSTEIN BARR VIRUS INFECTION; EXPANDED DISABILITY STATUS SCALE; FIRST DEGREE RELATIVE; GENETIC PREDISPOSITION; GENETIC RISK; HEARING IMPAIRMENT; HELMINTHIASIS; HERPES SIMPLEX; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INCIDENCE; INTESTINE FUNCTION DISORDER; LOWEST INCOME GROUP; MACROPHAGE; MCDONALD CRITERIA; MONOCYTE; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYELIN SHEATH; NERVE CELL; NERVE FIBER; NEUROIMAGING; NORTHERN HEMISPHERE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OCCUPATION; OLIGODENDROGLIA; PARESTHESIA; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS INFECTION; RADIATION EXPOSURE; REMYELINIZATION; SEX DIFFERENCE; SKIN TINGLING; SLURRED SPEECH; SMOKING; SOUTHERN HEMISPHERE; SUNLIGHT; TH1 CELL; TH17 CELL; TRIGEMINUS NEURALGIA; ULTRAVIOLET RADIATION; VERTIGO; WEAKNESS; DISEASE COURSE; FEMALE; MALE; PATHOPHYSIOLOGY; UNITED STATES;

DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; UNITED STATES;

EID: 84884396661     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. National Multiple Sclerosis Society. About MS: what we know about MS. http://www.nationalmssociety.org/about-multiplesclerosis/what-we-know-about-ms/ index.aspx. Accessed October 20, 2012.
2. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(suppl 5):S139-S145.
3. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520-532.
4. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387-A394.
5. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-955.
6. Prineas JW, Parratt JDE. Oligodendrocytes and the early multiple sclerosis lesion. Ann Neurol. 2012;72(1):18-31.
7. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17(5):604-609.
8. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103(15):5941-5946.
9. Kaur G, Trowsdale J, Fugger L. Natural killer cells and their receptors in multiple sclerosis [published online June 25, 2012]. Brain.
10. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6(10):1167-1175.
11. Wegner C, Stadelmann C, Pförtner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227(1-2):133-143.
12. Matusevicius D, Kivisäkk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5(2):101-104. (Pubitemid 29186827)
13. The International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-219.
14. Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188-2197.
15. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134(pt 7):1914-1924.
16. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
17. Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(suppl 5):S146-S153.
18. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430-1438.
19. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(pt 3):606-616. (Pubitemid 43278223)
20. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
21. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol. 2005;58(6):840-846. (Pubitemid 41746873)
22. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131(pt 3):808-817. (Pubitemid 351294716)
23. Rowland, LP, Pedley, TA. Merritt's Neurology. Philadelphia: Lippincott Williams & Wilkins; 2010.